Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity - PubMed (original) (raw)

Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity

J L Urban et al. J Exp Med. 1983.

Abstract

The ultraviolet radiation-induced fibrosarcoma 1591 is generally rejected by normal syngeneic mice, but occasionally the tumor succeeds in growing progressively. Analysis of these progressively growing tumors has regularly demonstrated the development of tumor variants that have acquired a heritable progressive growth potential. We have analyzed the phenotypic changes of these variants to determine which kind of selection pressure had occurred during the evolution of the variants, thus giving insight into the relative importance and hierarchy of the different immune defense mechanisms that may be operating in normal individuals as a defense against neoplastic cells. We discovered that all of the host-selected progressor variants had lost not only a strong T cell-recognized and tumor-specific antigen, but also their high sensitivity to cytotoxic macrophages. No selection for macrophage-resistance or loss of the tumor antigen was observed in 1591 tumors reisolated from idiotypically-suppressed mice or from other mice lacking tumor-specific T cell immunity. Analysis of other tumor variants selected in vitro showed that 1591 tumor cells have the potential to lose sensitivity to tumoricidal macrophages without losing the T cell-recognized tumor antigen. Thus the data suggest that T cells and macrophages act together to suppress the outgrowth of potentially malignant cells in vivo.

PubMed Disclaimer

Cited by

Characterization of gene expression profiles of T cells during anti-tumor response.
Stremmel C, Siebenhaar R, Croner R, Reingruber B, Slavin AJ, Hohenberger W. Stremmel C, et al. Int J Colorectal Dis. 2005 Nov;20(6):485-93. doi: 10.1007/s00384-004-0714-1. Epub 2005 Apr 6. Int J Colorectal Dis. 2005. PMID: 15812645
Inhibition of transcription factor nuclear factor-kappaB by a mutant inhibitor-kappaBalpha attenuates resistance of human head and neck squamous cell carcinoma to TNF-alpha caspase-mediated cell death.
Duffey DC, Crowl-Bancroft CV, Chen Z, Ondrey FG, Nejad-Sattari M, Dong G, Van Waes C. Duffey DC, et al. Br J Cancer. 2000 Nov;83(10):1367-74. doi: 10.1054/bjoc.2000.1423. Br J Cancer. 2000. PMID: 11044363 Free PMC article.
Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.
Wortzel RD, Urban JL, Schreiber H. Wortzel RD, et al. Proc Natl Acad Sci U S A. 1984 Apr;81(7):2186-90. doi: 10.1073/pnas.81.7.2186. Proc Natl Acad Sci U S A. 1984. PMID: 6609361 Free PMC article.
Evaluation of the interaction of mononuclear phagocytes with ovarian carcinoma cells in a colony assay.
Peri G, Zanaboni F, Rossini S, Mangioni C, Landoni F, Epis A, Mantovani A. Peri G, et al. Br J Cancer. 1986 Jan;53(1):47-52. doi: 10.1038/bjc.1986.7. Br J Cancer. 1986. PMID: 3947515 Free PMC article.
Macrophage infiltration and tumor progression.
Normann SJ. Normann SJ. Cancer Metastasis Rev. 1985;4(4):277-91. doi: 10.1007/BF00048093. Cancer Metastasis Rev. 1985. PMID: 3907821 Review. No abstract available.

References

1. J Exp Med. 1980 Apr 1;151(4):876-95 - PubMed
1. Eur J Immunol. 1979 Apr;9(4):283-8 - PubMed
1. J Immunol. 1981 Mar;126(3):981-7 - PubMed
1. J Immunol. 1981 May;126(5):1863-7 - PubMed
1. J Immunol. 1981 May;126(5):1985-9 - PubMed

Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity - PubMed (original) (raw)